Emerging pharmacologic therapies for wet age-related macular degeneration

Ophthalmologica

Volumn 223, Issue 6, 2009, Pages 401-410

  Ni, Zhang ^a,b,c   Hui, Peng ^a,b,c  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Chongqing Key Laboratory of Ophthalmology   (China)

^c Chongqing Survey Institute   (China)

Author keywords

Age related macular degeneration; Anti inflammatory; Antiangiogenesis; Choroidal neovascularization; Target therapy; Vascular epithelial growth factor

Indexed keywords

ACR 1905; AGN 21174; ANECORTAVE; ARC 1905; ATG 003; BEVACIZUMAB; BEVASIRANIB; COMBRETASTATIN A4 PHOSPHATE; E 10030; JSM 6427; MONTANIDE ISA 51; OT 551; PAZOPANIB; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; POT 4; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RAPAMYCIN; RECOMBINANT PROTEIN; SIRNA 027; TG 100801; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP EYE; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB; VERTEPORFIN; VOLOCIXIMAB;

ARTICLE; CLINICAL TRIAL; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOPHTHALMITIS; ENDOPTHALMITIS; HUMAN; LENS DISEASE; LENS INJURY; MONOTHERAPY; PHOTODYNAMICS; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; HUMANS; MACULAR DEGENERATION; WET MACULAR DEGENERATION;

EID: 67650705517     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228926     Document Type: Article

References (95)

1. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM: The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995; 36: 182-191.
2. Harvey PT: Common eye diseases of elderly people: identifying and treating causes of vision loss. Gerontology 2003; 49: 1-11.
3. Grossniklaus HE, Martinez JA, Brown VB, Lambert HM, Sternberg P, Capone A, et al: Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992; 114: 464-472.
4. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611. (Pubitemid 39099316)
5. Holmes DI, Zachary L: The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 2005; 6: 209.
6. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, et al: Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3186-3193.
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
8. Eyetech Study Group: Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143-152.
9. FDA, FDA Approves New Drug Treatment for Age-Related Macular Degeneration. http://www.fda.gov/bbs/topics/news/2004/ new01146.html (accessed December 20, 2004).
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
11. FDA, FDA Approves New Biologic Treatment for Wet Age-Related Macular Degeneration. http://www.fda.gov/bbs/topics/ NEWS/2006/NEW01405.html (accessed June 30, 2006).
12. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
13. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-248.
14. Antoszyk AN, Tuomi L, Chung CY, Singh A, and FOCUS Study Group: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145: 862-874.
15. Roberts D: SAILOR Study Results Favorable: Los Angeles: Bascom Palmer Eye Institute's Angiogenesis Meeting, 2008. http://www. mdsupport.org/library/ sailor.html (accessed February 23, 2008).
16. Singh RP: Highlights of the 26th Annual Meeting of the American Society of Retinal Specialists. http://www.medscape.com/ view article/582820 (accessed November 6, 2008).
17. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelveweek results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-1047.
18. FDA, FDA Approves First Angiogenesis Inhibitor to Treat Colorectal Cancer. http:// www.fda.gov/bbs/topics/NEWS/2004/ NEW01027.html (accessed February 26, 2004).
19. Bashshur ZF, Bazarbaachi A, Schakal A, Hassad ZA, El Haibi CP, Noureddin BN: Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1-9.
20. Ehrlich R, Weinberger D: Outcome of bevacizumab (Avastin) injection in patients with age-related macular degeneration and low visual acuity. Retina 2008; 28: 1302-1307.
21. Wolf A, Kook D, Strauss R, Kampik A, Haritoglou C: How to treat recurrences after Avastin treatment for neovascular AMD: stick to Avastin or switch to Lucentis? Br J Ophthalmol 2008; 92: 1297-1298.
22. MAAM Study: Avastin and Macugen versus Avastin versus Macugen. http://www.clinicaltrials. gov/ct2/show/NCT00531336?order=1 (accessed September 15, 2007).
23. Comparison of Age-Related Macular Degeneration Treatment Trials: Lucentis-Avastin Trial. http://clinicaltrials.gov/ct2/show/ NCT00593450?order=1 (accessed January 3, 2008).
24. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM: Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 2002; 143: 2797-2807.
25. Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA: A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 1521-1522.
26. Bayer Health Care and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2. http://www.medicalnewstoday. com/articles/ 119267.php (accessed August 26, 2008).
27. Double-Masked Study of Efficacy and Safety of IVT VEGF Trap-Eye in Subjects with Wet AMD (VIEW 1). http://www.clinicaltrials. gov/ct2/show/ NCT00509795?order=1 (accessed July 31, 2007).
28. Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2). http://clinicaltrials. gov/ct2/show/NCT00637377?order=1 (accessed March 12, 2008).
29. Acuity Pharmaceuticals Reports Positive Initial Phase II Results for Bevasiranib (Cand5) in Wet AMD. http://www.medicalnewstoday. com/articles/44387.php (accessed June 2, 2006).
30. Michels S, Schmidt-Erfurth U, Rosenfeld PJ: Promising new treatments for neovascular age-related macular degeneration. Expert Opin Investig Drugs 2006; 15: 779-793.
31. OPKO's SiRNA Drug for AMD Shows Promise. Accessed January 2008 at: http:// www.retinalphysician.com/article.aspx? article=101325
32. Safety and Efficacy Study Evaluating the Combination of Bevasiranib and Lucentis Therapy in Wet AMD (CARBON). http:// www. c l i n ic a l t r i a l s .gov/c t 2/show/ NCT00499590?order=1 (accessed July 10, 2007).
33. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
34. Zeng H, Dvorak HF, Muchopadhyay D: Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 2000; 159: 993-10008.
35. Hellström M, Gerhardt H, Kalén K, Li X, Eriksson U, Wolburg H, et al: Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001; 153: 543-553.
36. Benjamin LE, Hemo I, Keshet E: A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-1598.
37. Jo N, Maihos C, Ju M: Inhibition of plateletderived growth factor B signalling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006; 168: 2036-2053.
38. Doukas J, Mahesh S, Umeda N, Kachi S, Akiyama H, Yokoi K, et al: Topical administration of multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 2008; 216: 29-37.
39. Roberts D: Antiangiogenic drugs are stopping neovascularization in wet macular degeneration. http://www.mdsupport.org/ library/anti-angio.html (accessed January 2008).
40. Open-Label, Pilot Study of TG100801 in Patients with Choroidal Neovascularization due to AMD. http://www.clinicaltrials.gov/ ct2/show/NCT00509548?order=1 (accessed July 27, 2007).
41. Kaiser PK: Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142: 660-668.
42. Safety and Efficacy of Oral PTK787 in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) (ADVANCE). http://www.clinicaltrials.gov/ct2/show/ NCT00138632?order=1 (accessed August 29, 2005).
43. Sonpavde G, Hutson TE, Sternberg CN: Pazopanib, a potent orally administered smallmolecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 2008; 17: 253-261.
44. A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects with Neovascular AMD. http://www. clinicaltrials.gov/ct2/show/ NCT00612456?order=1 (accessed January 29, 2008).
45. Shen J, Sarmul R, Silva RL, Akiyama H, Liu H, Saishin Y, et al: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225-234.
46. Sirna Therapeutics Reports Final Results from Phase 1 Study on Its RNAi-Based Therapeutic for Age-Related Macular Degeneration. http://www.medicalnewstoday.com/ articles/49334.php (accessed August 11, 2006).
47. A Study Using Intravitreal Injections of a Small Interfering RNA in Patients with Age- Related Macular Degeneration. http://www. clinicaltrials.gov/ct/show/NCT 00395057? order=1 (accessed October 31, 2006).
48. Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH: IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001; 108: 51-62.
49. Mochimaru H, Nagai N, Hasegawa G, Kudo- Saito C, Yaguchi T, Usui Y, et al: Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2. Invest Ophthalmol Vis Sci 2007; 48: 4795-4801.
50. Anti-VEGFR Vaccine Therapy in Treating Patients with Neovascular Maculopathy. http://www.clinicaltrials.gov/ct2/show/ NCT00791570?order=1 (accessed October 31, 2008).
51. Bok D: Evidence for an inflammatory process in age-related macular degeneration gains new support. Proc Natl Acad Sci USA 2005; 102: 7053-7054.
52. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, et al: Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002; 8: 119-126.
53. Van der Schaft TL, Mooy CM, Bruijn WC, Jong PT: Early stages of age-related macular degeneration: an immunofluorescence and electron microscopic study. Br J Ophthalmol 1993; 81: 38-47.
54. Yang R, McColm JR, Bingaman DP, Penn JS: The effect of anecortave acetate on VEGF message and protein levels in hypoxic Muller cells and in rat OIR. Invest Ophthalmol Vis Sci 2005; 46:E-abstr 4177.
55. Liu C, Gu X, Wang W, Bingaman DO, Bingaman H: Local delivery of anecortave acetate inhibits the expression of retinal IGF-1/ IGF-1 receptor in the rat OIR model. Invest Ophthalmol Vis Sci 2005; 46:E-abstr 4135.
56. Clinical Policy Bulletin: Anecortave acetate (Retaane). http://www.aetna.com/cpb/medical/ data/700-799/0706.html (accessed November 2007).
57. Slakter JS, Bochow T, D'Amico DJ, Marks B, Jerdan J, Sullivan EK, et al: Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 113: 3-13.
58. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, et al: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 121: 667-673.
59. Uckermann O, Kutzera F, Wolf A, Pannicke T, Reichenbach A, Wiedemann P, et al: The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling. J Pharmacol Exp Ther 2005; 315: 1036-1045.
60. Nozaki M, Raisler BJ, Sakuri E, Baffi JZ, Ambati BK, Ambati J: Drusen complement components C3. Proc Natl Acad Sci USA 2006; 103: 2328-2333.
61. AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects during Phase I Clinical Trial. http://www.medicalnewstoday. com/articles/128837. php (accessed November 11, 2008).
62. ARC1905 (ANTI-C5 APTAMER) Given either in Combination Therapy with Lucentis® 0.5 mg/Eye in Subjects with Neovascular Age-Related Macular Degeneration. http://www.clinicaltrials.gov/ct2/show/ NCT00709527?order=1 (accessed July 1, 2008).
63. Treating Wet Form of AMD - Othera Eye Drop Data Shows Synergistic Effect with Lucentis and Avastin. http://www.medicalnewstoday. com/articles/63892.php (accessed February 26, 2007).
64. Christman JW, Lancaster LH, Blackwell TS: Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998; 24: 1131-1138.
65. OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration. http://www.clinicaltrials.gov/ ct2/show/NCT00306488?order= 1 (accessed March 22, 2006).
66. The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated with Age-Related Macular Degeneration (Dry AMD). http://www.clinicaltrials.gov/ ct2/ show/NCT00485394?order=1 (accessed June 11, 2007).
67. Pettit GR, Singh SB, Hamel E, Lin CM, Alerts DS, Garcia Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45: 209-211.
68. Tozer GM, Prise VE, Wilson J: Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413-6422.
69. Griggs DJ, Skepper JN, Smith GA, Brindle KM, Metcalfe JC, Hesketh R: Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol 2002; 160: 1097-1103.
70. OXiGENE-Newsrelease. OXiGENE Announces Interim Results of Wet Age-Related Macular Degeneration Trial of Combretastatin A4 Prodrug. http://www.oxigene. com/press/pressreleases.asp (accessed May 18, 2004).
71. OXiGENE-Newsrelease. OXiGENE Announces Positive Results from its Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213). http://www.oxigene. com/press/pressreleases.asp (accessed February 15, 2007).
72. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, et al: Pigment epithelium- derived factor suppresses ischemia-induced retinal neovascularization and VEGFinduced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-829.
73. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA: Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43: 2428-2434.
74. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, et al: Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17: 167-176.
75. Rasmussen H, Chu KW, Campochairo P, Gehlbach PL, Haller JA, Handa JT, et al: An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12: 2029-2032.
76. Maier AK, Kociok N, Zahn G, Vossmeyer D, Stragies R, Muether PS, Joussen AM: Modulation of hypoxia-induced neovascularization by JSM6427, an integrinα5β 1 inhibiting molecule. Curr Eye Res 2007; 32: 801-812.
77. Ramakrishnan B, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, et al: Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006; 5: 273-286.
78. A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD. http://clinicaltrials.gov/ct2/ show/NCT00536016?order=1 (accessed September 25, 2007).
79. Athenagen's Eye Drop Therapy for AMD Is Safe and Well Tolerated in Phase I Study. http://www.charterls.com/news-013107. html (accessed January 31, 2007).
80. Athenagen's Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study. http://www.charterls.com/news-013107. html (accessed January 31, 2007).
81. Safety and Efficacy of ATG003 in Patients with Wet Age-Related Macular Degeneration (AMD). http://www.clinicaltrials.gov/ ct2/show/NCT00414206?order=1 (accessed December 19, 2006).
82. Safety and Efficacy of ATG003 in Patients with AMD Receiving Anti-VEGF. http:// www. clinicaltrials .gov/c t 2/show/ NCT00607750?order=1 (accessed January 23, 2008).
83. Guba M, Breitenbuch PV, Geissler E, Koehl G, Steinbauer M, Jauch K: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
84. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J: Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004; 10: 964-972.
85. MacuSight TM Announces Positive Preliminary Results from Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration. http://www.medicalnewstoday. com/articles/ 98491.php (accessed February 26, 2008).
86. Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination with Lucentis® in Patients with Age-Related Macular Degeneration (EMERALD). http://www. clinicaltrials.gov/ct2/show/NCT00766337? order=1 (accessed October 1, 2008).
87. Roberts D: New Anti-PDGF Aptamer Now in Trials. http://www.mdsupport.org/ library/E10030.html (accessed February 15, 2008).
88. Glossary of Clinical Trials Terms. http:// clinicaltrials.gov/ct2/info/ glossary (accessed March 18, 2008).
89. Garcia C, Bartsch DU, Rivero ME, Hagedorn M, McDermott CD, Bergeron-Lynn G, et al: Efficacy of Prinomastat (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr Eye Res 2002; 24: 33-38.
90. Pharmacological Therapy for Macular Degeneration Study Group: Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 1997; 115: 865-872.
91. Maguire MG, Fine SL, Maguire AM, D'Amato RJ, Singerman LJ: Results of the age-related macular degeneration and thalidomide study (AMDATS). Invest Ophthalmol Vis Sci 2001; 42: 1233-1255.
92. Genaera Press Room: Genaera Corporation Terminates Evizon Clinical Program and Restructures. http://www.genaera.com/ press-room.php?page=133 (accessed January 3, 2007).
93. Endostatins Inhibiting Neovascularization to Aid Age-Related Macular Degeneration Treatment. http://www.medinewsdirect. com/?p=362 (accessed December 11, 2007).
94. Age-Related Macular Degeneration - Preclinical Efficacy Data with Retinostat(R). http://www.medicalnewstoday.com/articles/ 23896.php (accessed May 5, 2005).
95. Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140.